The Health Ministry has proposed allowing imported medicines to have a minimum of 12 months of shelf life remaining, moving away from the stricter 60% rule. This shift aims to reduce product wastage, which could help pharmaceutical importers lower costs and improve inventory efficiency, provided the proposal becomes final regulation.
What Happened
The Union Health Ministry has released a draft notification proposing a change in how the shelf life of imported drugs is calculated at the time of entry into India. Currently, imported drugs are required to have at least 60% of their total shelf life remaining when they reach the country. The proposed amendment seeks to replace this percentage-based rule with a simpler fixed requirement: imported drugs would only need a minimum of 12 months of shelf life left at the point of entry.
This proposal, released for public consultation on June 22, 2026, is aimed at easing the import process and reducing the instances where perfectly usable medicine must be discarded simply because it falls outside the rigid percentage calculation.
Why This Matters for Investors
For pharmaceutical companies that import specialized drugs, oncology products, or niche medicines, inventory management is a significant operational challenge. When imported drugs expire while sitting in warehouses or during transit due to strict residual shelf-life laws, companies are often forced to write them off as a loss. This creates wastage and hurts profit margins.
By moving to a flat 12-month rule, companies could have more flexibility in their supply chain. If implemented, this change may lead to better inventory control and lower operational costs for companies that rely on imports to sell high-value or essential drugs in the Indian market. While this is not a transformative change for companies primarily focused on domestic manufacturing, it is a positive step for those with import-heavy portfolios.
The Biological Exception
Investors should note that this proposal does not apply to all medicines. The Ministry has clearly stated that specialized categories, specifically biological products and radiopharmaceuticals, will continue to follow the existing, more stringent rule of requiring over 60% of their total shelf life. These products are often more sensitive to temperature and time, meaning their quality and safety standards remain critical. Therefore, companies with a heavy focus on importing complex biological drugs will not see a change in their current regulatory requirements.
Regulatory Reality Check
The current notification is a proposal open for public feedback, not an immediate change in law. The Ministry has confirmed that this adjustment is strictly about shelf-life requirements and does not alter the core safety, efficacy, or quality standards mandated under the Drugs and Cosmetics Act of 1940. The actual impact on company balance sheets will only be measurable after the final notification is issued and operationalized.
What Investors Should Track Next
Investors may want to watch for a few specific developments. First, the timeline for the final notification and whether the government addresses any industry feedback received during the consultation period. Second, keep an eye on management commentary in upcoming quarterly results from pharmaceutical firms that have significant import operations. Executives may clarify if this change will materially affect their inventory write-offs or profit margins in the coming years.